Declining sustained virological response in hepatitis C

Journal of the College of Physicians and Surgeons Pakistan

Volumn 16, Issue 3, 2006, Pages 187-191

  Uzma, Batool ^a   Qureshi, Saleem ^b  

^a KRL Hospital   (Pakistan)

^b NONE

Author keywords

HCV; Interferon; Response rates; Sustained viral response

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MIDDLE AGED; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 39049187018     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hepatitis C-global prevalence (update). Weekly Epidemiol Rec 1999; 49: 425-427
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(3 suppl): 62S-5S.
3. Zuberi SJ. International Hepatology Communications 1996; 5:19-26.
4. Moatter T, Hussainy AS, Hamid S, Ahmed Z, Siddiqui S. Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3, Int j Infect Dis 2002; 6: 272-276 (Pubitemid 36055134)
5. National Institute of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26 (3 suppl 1): 2S-10S.
6. Manns MP, McHutchison JG, Gordon SC, Rusgi VK, Shiftman M, Reindollar R, et al. Peglnterferon alfa 2-b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet 2001; 358: 958-965 (Pubitemid 32913521)
7. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease, Centers for Disease Control and Prevention. MMWR Remmm Rep 1998; 47 (RR19): 1-39.
8. Schaim SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26(3 suppl 1): 128S-32S.
9. Heathcote EJ, Shiftman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al Peglnterferon alfa-2a in patients with hepatitis C and cirrhosis. H Engl J Med 2000; 343: 1673-1680
10. Mc Hutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee Wall, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492 (Pubitemid 28543496)
11. Hadziyannis SJ, Cheinquet H, Morgan T. Peglnterferon-alfa 2a in combination with ribavirin: efficacy and safety results from phase III, randomized, double blind multi-center study examining effect of duration of treatment and RBV. J Hepatol 2002: 36 (suppl 1): 1.
12. Manns MP, Mc Hutchison JG, Gordon SC, Rustgi VK, Shiftman M, Reindollar R, et al. Peglnterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965 (Pubitemid 32913521)
13. Mangia A, Santero R, Minerva N, Ricci GL, Carretta V, Persico M, et al Peglnterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617 (Pubitemid 41007847)
14. Shaikh WM, Shaikh MA, Solangi GA, Zuberi BF. Role of interferon and interferon plus ribavirin in the management of chronic hepatitis C. J Coll Physicians Surg Pak 2002; 12: 609-612 (Pubitemid 36032896)
15. Hussein AB, Hussein T, Anwar M, Shujaat H, Kazmi Y, 'Tariq WZ, Karamat KA. Treatment response in HCV related chronic hepatitis. J Cull Physicians Surg Pak 2002; 12: 609-612
16. Noor M, Jan MA, Rahman N. Treatment response of hepatitis C patients to combination therapy of interferon plus ribavirin, J Postgrad Med Inst 2004; 18:563-568
17. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks versus interfern alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis International Therapy Group (IHIT). Lancet 1998, 352: 1426-1432 (Pubitemid 28510876)
18. Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
19. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C patients with normal or abnormal alanine transaminase levels. Hepatology 1997; 26 (3 suppl 1): 133S-6S.
20. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P. et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-1398 (Pubitemid 27520001)
21. Gholson CF, Morgan K, Catinis G, Favrat D, Taylor B, Gonzalez E. et al, Chronic hepatitis C with normal aminotransferase ievels: a Clnical histologic study. Am J Gastroenterol 1997, 92: 1788-1792 (Pubitemid 27440891)
22. Westin J, Nordlinder H, Lagging M, Norkrans G, Wojstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37; 837-842 (Pubitemid 35404224)
23. Monto A. Hepatitis C and steatosis. Semin Gastrolntest Dis 2002; 13: 40-46
24. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35: 307. (Pubitemid 32807717)